Brief: Hoth Therapeutics Announces Groundbreaking Positive Results Hoth's Ht-Va Gdnf Surpasses Semaglutide In Weight Loss
10/02/2026 13:42
Feb 10 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS ANNOUNCES GROUNDBREAKING POSITIVE RESULTS: HOTH'S HT-VA GDNF SURPASSES SEMAGLUTIDE IN WEIGHT LOSS, GLUCOSE CONTROL, AND LIVER HEALTH IN OBESITY MODEL HOTH THERAPEUTICS INC - GDNF REDUCES LIVER WEIGHT BY 20-30% HOTH THERAPEUTICS INC - GDNF ATTENUATES WEIGHT GAIN BY 10-15% LEADING TO A PLATEAU IN THE FINAL WEEKS OF TREATMENT Source text: ID:nPn4Cl3D6a Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology